SBH logo

Sangui Biotech International HMSE:SBH Stock Report

Last Price

€0.002

Market Cap

€419.8k

7D

0%

1Y

-60.0%

Updated

23 Apr, 2024

Data

Company Financials

Sangui Biotech International, Inc.

HMSE:SBH Stock Report

Market Cap: €419.8k

SBH Stock Overview

Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products.

SBH fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Sangui Biotech International, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sangui Biotech International
Historical stock prices
Current Share Price€0.002
52 Week High€0.009
52 Week Low€0.002
Beta-0.33
1 Month Change0%
3 Month Change-33.33%
1 Year Change-60.00%
3 Year Change-90.00%
5 Year Change-92.00%
Change since IPO-99.94%

Recent News & Updates

Recent updates

Shareholder Returns

SBHDE BiotechsDE Market
7D0%-3.1%1.8%
1Y-60.0%-22.4%2.2%

Return vs Industry: SBH underperformed the German Biotechs industry which returned -21.1% over the past year.

Return vs Market: SBH underperformed the German Market which returned -0.3% over the past year.

Price Volatility

Is SBH's price volatile compared to industry and market?
SBH volatility
SBH Average Weekly Movement22.9%
Biotechs Industry Average Movement5.0%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: SBH's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine SBH's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1995n/aThomas Striepewww.sanguibiotech.com

Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. The company offers artificial oxygen carriers comprising oxygen carrying blood additives and oxygen carrying blood volume substitutes; nano formulations for the regeneration of skin; chitoskin wound pads; Hemospray, a hemoglobin based wound spray; and wound dressing spray under the Granulox brand. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany.

Sangui Biotech International, Inc. Fundamentals Summary

How do Sangui Biotech International's earnings and revenue compare to its market cap?
SBH fundamental statistics
Market cap€419.80k
Earnings (TTM)-€93.80k
Revenue (TTM)€90.00k

4.7x

P/S Ratio

-4.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SBH income statement (TTM)
RevenueUS$96.26k
Cost of RevenueUS$0
Gross ProfitUS$96.26k
Other ExpensesUS$196.58k
Earnings-US$100.32k

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.00048
Gross Margin100.00%
Net Profit Margin-104.22%
Debt/Equity Ratio-72.8%

How did SBH perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.